Jafron Biomedical Co

Jafron Biomedical Co Pre-Tax Margin

The Pre-Tax Profit Margin of Jafron Biomedical Co (300529.SZ) as of Nov 13, 2026 is 32.81 %. In the previous year, Pre-Tax Profit Margin was 37.61 % — a change of -12.76% (lower).

Pre-Tax Margin

32.81 %

YoY

-12.76%

Last updated:

Pre-Tax Profit Margin of Jafron Biomedical Co is 2025 32.81 % . Pre-Tax Profit Margin of Jafron Biomedical Co was 2024 37.61 % . It decreases by -12.76% lower compared to the previous year.

The Jafron Biomedical Co Pre-Tax Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Pre-Tax Margin
Date
Pre-Tax Margin
Jan 1, 2018
46.55 CNY
Jan 1, 2019
46.88 CNY
Jan 1, 2020
52.90 CNY
Jan 1, 2021
52.60 CNY
Jan 1, 2022
40.81 CNY
Jan 1, 2023
27.10 CNY
Jan 1, 2024
37.61 CNY
Jan 1, 2025
32.81 CNY
The Jafron Biomedical Co Pre-Tax Margin history
YEARPre-Tax MarginYoY
32.81 %-12.76%
37.61 %+38.77%
27.10 %-33.59%
40.81 %-22.41%
52.60 %-0.57%
52.90 %+12.83%
46.88 %+0.73%
46.55 %-1.68%
47.34 %+6.59%
44.42 %-5.75%
47.13 %-8.53%
51.52 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Jafron Biomedical Co Stock analysis

What does Jafron Biomedical Co do? Jafron Biomedical Co., Ltd. generates revenue through the research, development, production, and sale of hemoperfusion products and medical equipment. The company offers a range of items including disposable hemoperfusion devices, hemoperfusion machines, disposable bilirubin adsorbers, the DX-10 blood purification machine, suture needles, and resins bandage. These products are utilized for treating conditions such as uremia, poisoning, severe liver diseases, autoimmune diseases, and multisystem organ failure. The primary customers for these medical solutions are hospitals across China, where the company’s products are applied in more than 3000 hospitals within 31 provinces. As a China-based company, Jafron Biomedical Co., Ltd. focuses on the design, manufacture, and distribution of biological materials and medical equipment to support healthcare providers in these regions. The company operates from its headquarters in Zhuhai, Guangdong, and supports its operations with a workforce of 3,003 full-time employees. By engaging in the full lifecycle of its products from research to sale, the firm serves the medical sector with specialized equipment for blood purification and related therapeutic needs. Jafron Biomedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Jafron Biomedical Co stock

Pre-Tax Profit Margin of Jafron Biomedical Co is 32.81 % in 2025.

Pre-Tax Profit Margin of Jafron Biomedical Co changed from 37.61 % to 32.81 %, representing a -12.76% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Pre-Tax Profit Margin Jafron Biomedical Co since 2006 – with annual values, charts, and detailed analysis.

Pre-tax margin measures the percentage of revenue remaining after all expenses except income taxes. It isolates operational and financial performance from tax effects.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Pre-Tax Profit Margin's Jafron Biomedical Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Pre-Tax Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Pre-Tax Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Jafron Biomedical Co

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Jafron Biomedical Co